Treatment paradigms for patients with type 2 diabetes mellitus (DM) and heart failure (HF) has changed. Sodium glucose cotransporter 2 inhibitors, such as empagliflozin, are now considered potential first line therapies. Compliance to empagliflozin and the factors that may influence compliance are unknown. Methods: We assessed compliance and associated factors in patients with DM and HF from Veterans Affairs national data from 2015-22. Compliance was calculated using proportion of days covered (PDC). Compliance to empagliflozin was defined as PDC > 80%. Patients who compliance could not be calculated were excluded. Generalized linear models were constructed to evaluate 1) demographic, 2) patient level, and 3) system level data.
Results: Total 28,581 patients exposed to empagliflozin were included. Proportion of empagliflozin compliance was 66.2%. Table 1 displays the significant demographic, patient, and system level factors associated with poor empagliflozin compliance.
Conclusions: There were demographic, patient, and system level factors that were associated with poor empagliflozin compliance.
C.A.Alvarez: Research Support; Boehringer Ingelheim Inc. A.Perkins: None. M.A.Sigler: None. H.Yang: None. H.Caberwal: Employee; Boehringer Ingelheim Inc. R.Ebrahimi: Consultant; Pfizer Inc., Speaker's Bureau; Novo Nordisk.
Boehringer Ingelheim
